000285034 001__ 285034
000285034 005__ 20260206170625.0
000285034 0247_ $$2doi$$a10.1177/1877718X251365243
000285034 0247_ $$2pmid$$apmid:41252262
000285034 0247_ $$2ISSN$$a1877-7171
000285034 0247_ $$2ISSN$$a1877-718X
000285034 037__ $$aDZNE-2026-00159
000285034 041__ $$aEnglish
000285034 082__ $$a610
000285034 1001_ $$00000-0003-2133-714X$$aD'Souza, Simone$$b0
000285034 245__ $$aFear of progression in Parkinson's disease: Role of age and occupational status.
000285034 260__ $$aAmsterdam$$bIOS Press$$c2026
000285034 3367_ $$2DRIVER$$aarticle
000285034 3367_ $$2DataCite$$aOutput Types/Journal article
000285034 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770393847_716
000285034 3367_ $$2BibTeX$$aARTICLE
000285034 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285034 3367_ $$00$$2EndNote$$aJournal Article
000285034 520__ $$aBackground: Parkinson's disease (PD) is a slowly progressing neurodegenerative disorder, so it is likely that people with PD (PwPD) face increasing disability. PwPD thus experience various degrees of fear of progression (FoP), which can become dysfunctional. Objective: This study aims to examine the prevalence of and contributing factors to dysfunctional FoP in PwPD. Methods: The Fear of Progression Questionnaire-Short Form (FoP-Q-SF) was administered along with further questionnaires for non-motor symptoms; PD motor symptoms as reported by the Unified Parkinson's Disease Rating Scale Part III (UPDRS III) were obtained from patient charts. Results: 28% of the 105 PwPD (mean age 66 years, 56% Hoehn & Yahr stage I/II) were categorized as experiencing dysfunctional levels of FoP using the established cut-off score of ≥34. Our analyses revealed that the FoP-Q-SF underestimates the prevalence of dysfunctional FoP in older and non-working PwPD. Using a more appropriate cut-off, 33% of PwPD are classified as having dysfunctional levels of FoP. We found strong correlations of FoP with measures of anxiety, depression and quality of life. Disease duration was secondary to these factors. We found no associations between FoP and motor symptoms. Conclusions: Our findings confirm that dysfunctional FoP significantly impacts the psychological well-being of PwPD, affecting one in three PwPD and contributing to heightened anxiety, depression, and reduced quality of life. Future validation studies are needed to confirm the cut-off value proposed here and to enable a better integration of the concept of FoP into routine care for PwPD.
000285034 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285034 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285034 650_7 $$2Other$$aParkinson's disease
000285034 650_7 $$2Other$$aanxiety
000285034 650_7 $$2Other$$adepression
000285034 650_7 $$2Other$$adistress
000285034 650_7 $$2Other$$afear of progression
000285034 650_7 $$2Other$$anon-motor symptoms
000285034 650_2 $$2MeSH$$aHumans
000285034 650_2 $$2MeSH$$aParkinson Disease: psychology
000285034 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000285034 650_2 $$2MeSH$$aAged
000285034 650_2 $$2MeSH$$aMale
000285034 650_2 $$2MeSH$$aFemale
000285034 650_2 $$2MeSH$$aDisease Progression
000285034 650_2 $$2MeSH$$aMiddle Aged
000285034 650_2 $$2MeSH$$aFear: psychology
000285034 650_2 $$2MeSH$$aAge Factors
000285034 650_2 $$2MeSH$$aEmployment: statistics & numerical data
000285034 650_2 $$2MeSH$$aEmployment: psychology
000285034 650_2 $$2MeSH$$aAnxiety: psychology
000285034 650_2 $$2MeSH$$aAnxiety: epidemiology
000285034 650_2 $$2MeSH$$aQuality of Life: psychology
000285034 650_2 $$2MeSH$$aAged, 80 and over
000285034 650_2 $$2MeSH$$aDepression: psychology
000285034 650_2 $$2MeSH$$aDepression: epidemiology
000285034 650_2 $$2MeSH$$aSurveys and Questionnaires
000285034 7001_ $$aTekampe, Esther$$b1
000285034 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b2
000285034 7001_ $$0P:(DE-2719)9003291$$aSchnalke, Nils$$b3$$eLast author
000285034 773__ $$0PERI:(DE-600)2599550-9$$a10.1177/1877718X251365243$$gVol. 16, no. 1, p. 170 - 176$$n1$$p170 - 176$$tJournal of Parkinson's Disease$$v16$$x1877-7171$$y2026
000285034 8564_ $$uhttps://pub.dzne.de/record/285034/files/DZNE-2026-00159.pdf$$yRestricted
000285034 8564_ $$uhttps://pub.dzne.de/record/285034/files/DZNE-2026-00159.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285034 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285034 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003291$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285034 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285034 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PARKINSON DIS : 2022$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-10-23T11:51:45Z
000285034 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-10-23T11:51:45Z
000285034 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review, Double anonymous peer review$$d2024-10-23T11:51:45Z
000285034 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ PARKINSON DIS : 2022$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000285034 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000285034 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x0
000285034 980__ $$ajournal
000285034 980__ $$aEDITORS
000285034 980__ $$aVDBINPRINT
000285034 980__ $$aI:(DE-2719)1710012
000285034 980__ $$aUNRESTRICTED